The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
HOME > BUSINESS
BUSINESS
- Concurrent-Use Indications Approved for Trazenta: NBI, Eli Lilly Japan
March 27, 2013
- ASKA Targets Sales of 50 Billion yen in FY2015, Up 20% vs. FY2012 Outlook: 3-Year Plan
March 27, 2013
- New Parkinson’s Disease Treatment Nouriast Approved: Kyowa Kirin
March 27, 2013
- FD Treatment Acofide Approved: Zeria, Astellas
March 27, 2013
- Otsuka Receives Approval for DPP-4 Inhibitor Onglyza, to Transfer Marketing Rights to Kyowa Kirin
March 27, 2013
- Takeda Announces Full Cancellation of Correction Notice Based on Transfer Pricing Tax System; 15.2 Billion Yen Refund Expected
March 27, 2013
- Marc Dunoyer Steps Down as Chairman of GSK K.K.
March 26, 2013
- Terumo Launches Cancer Pain Treatment Methapain
March 26, 2013
- Takeda Files NDA for Malignant Lymphoma Treatment Brentuximab Vedotin in Japan
March 26, 2013
- JAK Inhibitor Xeljanz Approved for RA: Pfizer Japan
March 26, 2013
- Regtect Approved for Supporting Maintenance of Abstinence in Patients with Alcohol Dependence: Nippon Shinyaku
March 26, 2013
- Daiichi Sankyo Aims for Approval of Enbrel Biosimilar in FY2016: President Nakayama
March 26, 2013
- Daiichi Sankyo’s Osteoporosis Treatment Pralia Approved
March 26, 2013
- New Settai Rules Halfway to Establishment; Some in Industry Want Further Rules as Well
March 26, 2013
- Astellas Ties Up with Tokyo Tech and Nagasaki University to Research Anti-Dengue Virus Treatment
March 25, 2013
- Daiichi Sankyo Mulls Biz Platform after Olmesartan LOE: New 5 Year Plan
March 25, 2013
- Takeda Returns Global Rights to NPS Pharmaceuticals for Preotact and Revestive
March 25, 2013
- Israeli-Originated High-Techs Highlighted at Israel Life Science Forum 2013
March 25, 2013
- Merck Serono to Develop Anticancer Drugs for Asian Patients at R&D Hub in Tokyo
March 22, 2013
- New Product Launches “On Track,” Sales Brisk: Otsuka Holdings Pres. Higuchi
March 22, 2013
ページ
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…